Legal & General Group’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-4,813
| Closed | -$19.3K | – | 3429 |
|
|
2025
Q2 | $19.3K | Hold |
4,813
| – | – | ﹤0.01% | 3015 |
|
|
2025
Q1 | $4.38K | Hold |
4,813
| – | – | ﹤0.01% | 3297 |
|
|
2024
Q4 | $13.3K | Hold |
4,813
| – | – | ﹤0.01% | 3174 |
|
|
2024
Q3 | $25.2K | Buy |
4,813
+780
| +19% | +$4.05K | ﹤0.01% | 2957 |
|
|
2024
Q2 | $18K | Hold |
4,033
| – | – | ﹤0.01% | 3066 |
|
|
2024
Q1 | $30.9K | Hold |
4,033
| – | – | ﹤0.01% | 2847 |
|
|
2023
Q4 | $17.2K | Buy |
4,033
+1,053
| +35% | +$3.74K | ﹤0.01% | 3091 |
|
|
2023
Q3 | $12.5K | Sell |
2,980
-275
| -8% | -$1.4K | ﹤0.01% | 3219 |
|
|
2023
Q2 | $18.1K | Buy |
+3,255
| New | +$19.2K | ﹤0.01% | 3147 |
|
|
2022
Q2 | – | Sell |
-1,147
| Closed | -$5K | – | 3591 |
|
|
2022
Q1 | $5K | Hold |
1,147
| – | – | ﹤0.01% | 3505 |
|
|
2021
Q4 | $8K | Hold |
1,147
| – | – | ﹤0.01% | 3495 |
|
|
2021
Q3 | $13K | Hold |
1,147
| – | – | ﹤0.01% | 3402 |
|
|
2021
Q2 | $20K | Sell |
1,147
-70
| -6% | -$1.22K | ﹤0.01% | 3293 |
|
|
2021
Q1 | $24K | Buy |
1,217
+323
| +36% | +$7.13K | ﹤0.01% | 3054 |
|
|
2020
Q4 | $18K | Hold |
894
| – | – | ﹤0.01% | 3133 |
|
|
2020
Q3 | $23K | Buy |
+894
| New | +$22.2K | ﹤0.01% | 2936 |
|
Legal & General Group's INZY Position: Q3 2025 in Review
Legal & General Group sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 4,813 shares — an estimated $19.3K sold.
Legal & General Group first reported a position in INZY in Q3 2020 and held it in 16 quarters. The position peaked at $30.9K in Q1 2024. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.
- Legal & General Group reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
- Legal & General Group sold 4,813 Inozyme Pharma shares in Q3 2025, an estimated $19.3K.
- Legal & General Group first reported a position in Inozyme Pharma in Q3 2020 and held it in 16 quarters.
- Legal & General Group's Inozyme Pharma position peaked at $30.9K in Q1 2024.
- 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.
Based on Legal & General Group's 13F filing for Q3 2025, filed 13 Nov 2025.